-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 19, the information on the pending drug approval documents of the State Food and Drug Administration showed that Osaikang Pharmaceutical's Enpagliflozin Tablets had been approved for marketing
Enpagliflozin is an SGLT2 inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly and Company, which is taken orally once a day
In the United States, Enpagliflozin has been approved by the FDA to treat multiple indications
A few days ago, the FDA also granted priority review qualification for the Supplementary New Drug Application (sNDA) of Enpagliflozin to reduce the risk of cardiovascular death and hospitalization in patients with heart failure, regardless of the patient’s left ventricular ejection fraction
According to the Canadian Heart Failure Guidelines in 2021, based on sufficient clinical research evidence, the core position of SGLT-2 inhibitors in the treatment of heart failure has been affirmed
At present, Engligliflozin tablets have been approved for listing by the pharmaceutical companies such as Hausen Pharmaceuticals, Kelun Pharmaceuticals, Chia Tai Tianqing, and Wanbang Pharmaceutical.
